GlassScriptPhysician profile
Zeynep Kucuk
NPI 1891924031
$1,089.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $389 · 2023: $42.85 · 2024: $55.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $318.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $159.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $74.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.54 | 2021-2024 | Cuvitru |
| Pfizer INC. | $61.92 | 2021 | |
| Alk-Abello, INC | $53.65 | 2021-2022 | |
| Genentech USA, INC. | $40.72 | 2021 | |
| Grifols USA, LLC | $27.69 | 2022 | |
| Pharming Healthcare, INC. | $22.04 | 2024 | Ruconest |
| Horizon Therapeutics Plc | $22.04 | 2023 | Actimmune |
| Kaleo, INC. | $20.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeynep Kucuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.